"Nvidia Magic" Strikes Again! Exploring Nvidia's Latest AI Investment Landscape

Moomoo News Global24minutes ago

BofA Securities Cuts Price Target on Recursion Pharmaceuticals to $10 From $12, Maintains Neutral Rating

MT Newswires11:13 ET · Ratings

Recursion Pharmaceuticals Announces 2 Key Investigational Oncology Drugs Advancing To Clinical Trials, Targeting High Unmet Needs In Hematologic Malignancies, Small-Cell Lung Cancer, & More

BenzingaJan 7 09:16 ET

Express News | Recursion Pharmaceuticals Inc - First Patient to Be Dosed in Phase 1 Excelerize Trial in Q1 2025

ReutersJan 7 09:15 ET

Express News | Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

ReutersJan 7 09:15 ET

BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $10

Moomoo NewsJan 7 08:35 ET · Ratings